GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme: A Retrospective Multi-Institutional Pilot Study

James Welsh, Abhay Sanan, Arash J. Gabayan, Sylvan B. Green, Robert Lustig, Stuart Burri, Edmund Kwong, Baldassarre Stea

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To report on a retrospective analysis of the cumulative experience from eight institutions using the GliaSite Radiotherapy System as a brachytherapy boost in the initial management of glioblastoma multiforme. Methods and Materials: Eight institutions provided data on 20 patients with histologically proven glioblastoma multiforme with a median age of 59 years (range, 39-76) and median Karnofsky performance scale of 80 (range, 50-100). After maximal surgical debulking, patients were treated with GliaSite brachytherapy to a median dose of 50 Gy, followed by external beam radiotherapy to a median dose of 60 Gy (range, 46-60 Gy), for a cumulative dose escalation of 110 Gy (range, 84-130 Gy). Results: The average survival for this study population was 11.4 months (range, 4-29). When the patients' survival was compared with that of historical controls according to their Radiation Therapy Oncology Group recursive partitioning analysis class, the average survival was increased by 3 months (95% confidence interval, 0.23-4.9) corresponding to a 43% increase (p = 0.033). Three patients (14%) experienced Radiation Therapy Oncology Group Grade 3 central nervous system toxicity. Of the treatment failures, 50% were >2 cm from the edge of the balloon. Conclusion: The results of this analysis have demonstrated that dose escalation (>100 Gy) with GliaSite is well tolerated and associated with minimal toxicity. Local control improved with the use of GliaSite brachytherapy. The putative survival advantage seen in this study needs to be interpreted with caution; nevertheless, the data provide sufficient justification to investigate the potential role of radiation dose escalation in conjunction with GliaSite in the initial treatment of glioblastoma multiforme.

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume68
Issue number1
DOIs
StatePublished - May 1 2007

Fingerprint

Brachytherapy
Glioblastoma
acceleration (physics)
Radiotherapy
radiation therapy
dosage
Radiation Oncology
Survival
toxicity
Karnofsky Performance Status
Therapeutics
Treatment Failure
central nervous system
balloons
Central Nervous System
Confidence Intervals
Radiation
confidence
grade
intervals

Keywords

  • Brachytherapy boost
  • Dose escalation
  • GliaSite
  • Glioblastoma multiforme
  • Malignant astrocytoma
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme : A Retrospective Multi-Institutional Pilot Study. / Welsh, James; Sanan, Abhay; Gabayan, Arash J.; Green, Sylvan B.; Lustig, Robert; Burri, Stuart; Kwong, Edmund; Stea, Baldassarre.

In: International Journal of Radiation Oncology Biology Physics, Vol. 68, No. 1, 01.05.2007, p. 159-165.

Research output: Contribution to journalArticle

Welsh, James ; Sanan, Abhay ; Gabayan, Arash J. ; Green, Sylvan B. ; Lustig, Robert ; Burri, Stuart ; Kwong, Edmund ; Stea, Baldassarre. / GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme : A Retrospective Multi-Institutional Pilot Study. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 68, No. 1. pp. 159-165.
@article{659fba41802447af9c0b4ab9df8c2751,
title = "GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme: A Retrospective Multi-Institutional Pilot Study",
abstract = "Purpose: To report on a retrospective analysis of the cumulative experience from eight institutions using the GliaSite Radiotherapy System as a brachytherapy boost in the initial management of glioblastoma multiforme. Methods and Materials: Eight institutions provided data on 20 patients with histologically proven glioblastoma multiforme with a median age of 59 years (range, 39-76) and median Karnofsky performance scale of 80 (range, 50-100). After maximal surgical debulking, patients were treated with GliaSite brachytherapy to a median dose of 50 Gy, followed by external beam radiotherapy to a median dose of 60 Gy (range, 46-60 Gy), for a cumulative dose escalation of 110 Gy (range, 84-130 Gy). Results: The average survival for this study population was 11.4 months (range, 4-29). When the patients' survival was compared with that of historical controls according to their Radiation Therapy Oncology Group recursive partitioning analysis class, the average survival was increased by 3 months (95{\%} confidence interval, 0.23-4.9) corresponding to a 43{\%} increase (p = 0.033). Three patients (14{\%}) experienced Radiation Therapy Oncology Group Grade 3 central nervous system toxicity. Of the treatment failures, 50{\%} were >2 cm from the edge of the balloon. Conclusion: The results of this analysis have demonstrated that dose escalation (>100 Gy) with GliaSite is well tolerated and associated with minimal toxicity. Local control improved with the use of GliaSite brachytherapy. The putative survival advantage seen in this study needs to be interpreted with caution; nevertheless, the data provide sufficient justification to investigate the potential role of radiation dose escalation in conjunction with GliaSite in the initial treatment of glioblastoma multiforme.",
keywords = "Brachytherapy boost, Dose escalation, GliaSite, Glioblastoma multiforme, Malignant astrocytoma, Radiotherapy",
author = "James Welsh and Abhay Sanan and Gabayan, {Arash J.} and Green, {Sylvan B.} and Robert Lustig and Stuart Burri and Edmund Kwong and Baldassarre Stea",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2006.11.053",
language = "English (US)",
volume = "68",
pages = "159--165",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - GliaSite Brachytherapy Boost as Part of Initial Treatment of Glioblastoma Multiforme

T2 - A Retrospective Multi-Institutional Pilot Study

AU - Welsh, James

AU - Sanan, Abhay

AU - Gabayan, Arash J.

AU - Green, Sylvan B.

AU - Lustig, Robert

AU - Burri, Stuart

AU - Kwong, Edmund

AU - Stea, Baldassarre

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Purpose: To report on a retrospective analysis of the cumulative experience from eight institutions using the GliaSite Radiotherapy System as a brachytherapy boost in the initial management of glioblastoma multiforme. Methods and Materials: Eight institutions provided data on 20 patients with histologically proven glioblastoma multiforme with a median age of 59 years (range, 39-76) and median Karnofsky performance scale of 80 (range, 50-100). After maximal surgical debulking, patients were treated with GliaSite brachytherapy to a median dose of 50 Gy, followed by external beam radiotherapy to a median dose of 60 Gy (range, 46-60 Gy), for a cumulative dose escalation of 110 Gy (range, 84-130 Gy). Results: The average survival for this study population was 11.4 months (range, 4-29). When the patients' survival was compared with that of historical controls according to their Radiation Therapy Oncology Group recursive partitioning analysis class, the average survival was increased by 3 months (95% confidence interval, 0.23-4.9) corresponding to a 43% increase (p = 0.033). Three patients (14%) experienced Radiation Therapy Oncology Group Grade 3 central nervous system toxicity. Of the treatment failures, 50% were >2 cm from the edge of the balloon. Conclusion: The results of this analysis have demonstrated that dose escalation (>100 Gy) with GliaSite is well tolerated and associated with minimal toxicity. Local control improved with the use of GliaSite brachytherapy. The putative survival advantage seen in this study needs to be interpreted with caution; nevertheless, the data provide sufficient justification to investigate the potential role of radiation dose escalation in conjunction with GliaSite in the initial treatment of glioblastoma multiforme.

AB - Purpose: To report on a retrospective analysis of the cumulative experience from eight institutions using the GliaSite Radiotherapy System as a brachytherapy boost in the initial management of glioblastoma multiforme. Methods and Materials: Eight institutions provided data on 20 patients with histologically proven glioblastoma multiforme with a median age of 59 years (range, 39-76) and median Karnofsky performance scale of 80 (range, 50-100). After maximal surgical debulking, patients were treated with GliaSite brachytherapy to a median dose of 50 Gy, followed by external beam radiotherapy to a median dose of 60 Gy (range, 46-60 Gy), for a cumulative dose escalation of 110 Gy (range, 84-130 Gy). Results: The average survival for this study population was 11.4 months (range, 4-29). When the patients' survival was compared with that of historical controls according to their Radiation Therapy Oncology Group recursive partitioning analysis class, the average survival was increased by 3 months (95% confidence interval, 0.23-4.9) corresponding to a 43% increase (p = 0.033). Three patients (14%) experienced Radiation Therapy Oncology Group Grade 3 central nervous system toxicity. Of the treatment failures, 50% were >2 cm from the edge of the balloon. Conclusion: The results of this analysis have demonstrated that dose escalation (>100 Gy) with GliaSite is well tolerated and associated with minimal toxicity. Local control improved with the use of GliaSite brachytherapy. The putative survival advantage seen in this study needs to be interpreted with caution; nevertheless, the data provide sufficient justification to investigate the potential role of radiation dose escalation in conjunction with GliaSite in the initial treatment of glioblastoma multiforme.

KW - Brachytherapy boost

KW - Dose escalation

KW - GliaSite

KW - Glioblastoma multiforme

KW - Malignant astrocytoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=34247154809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247154809&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.11.053

DO - 10.1016/j.ijrobp.2006.11.053

M3 - Article

C2 - 17331666

AN - SCOPUS:34247154809

VL - 68

SP - 159

EP - 165

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -